Clinical Trials Browser

Phase 2 × OTHER_GOV × camrelizumab × Clear all

NCT05475678 2025-01-23

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05355168 2024-12-31

Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Drug-Related Side Effects and Adverse Reactions

NCT06231680 2024-03-29

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Phase 2 Unknown

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

NCT05189483 2024-02-07

Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.

Phase 2 Unknown

Sarcoma

NCT05624099 2023-10-19

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Phase 2 Recruiting

Gastrointestinal

Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms

NCT04901754 2021-12-08

CAMERA

Phase 2 Unknown

Small Cell Lung Carcinoma

NCT04832204 2021-04-05

Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases

Phase 2 Unknown

Other solid neoplasm

Solid Tumor

NCT04102982 2020-11-02

MWA in NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03986515 2019-06-14

Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

Phase 2 Unknown

Mucosal Melanoma

NCT03755115 2019-01-16

SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer

Phase 2 Unknown

Small Cell Lung Cancer Extensive Stage